Tyra Biosciences, Inc. Common Stock
$25.43
$0.36 (+1.44%)
$24.15Day Range$25.77
Key Statistics
Market Cap
$1.50B
Shares Outstanding
59.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 15, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$24.71
Day High
$25.77
Day Low
$24.15
Volume
1.14M
VWAP
$25.31
Prev Close
$25.07
Transactions
--
Acc. Volume
--
About Tyra Biosciences, Inc. Common Stock
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
PHARMACEUTICAL PREPARATIONSSIC 283487 employees2656 STATE STREET, CARLSBAD, CA, 92008(619) 728-4760IPO Sep 15, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001863127
- Composite FIGI
- BBG00RCQD9D1
- Share Class FIGI
- BBG00RCQD9F9
- Ticker Root
- TYRA
- SIC Code
- 2834
About Tyra Biosciences, Inc. Common Stock (TYRA) Stock
Tyra Biosciences, Inc. Common Stock (TYRA) closed the 2026-09-15 session at $25.43, up 1.44% versus the previous close (+0.36). The stock opened at $24.71 and traded between $24.15 and $25.77 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $25.31.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tyra Biosciences, Inc. Common Stock has a market capitalization of $1.50 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TYRA is listed on the XNAS exchange. The company employs approximately 87 people. Tyra Biosciences, Inc. Common Stock is headquartered in CARLSBAD, CA. The recorded listing date is 2021-09-15.
On this page you can find market TYRA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.